Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
What happened
FDA inspected Bentley Laboratories LLC's drug manufacturing facility in Edison, NJ, from March 16 to 27, 2026, and found CGMP violations: inadequate investigations of out-of-specification results, inadequate testing of incoming components for identity and hazardous impurities, and inadequate process and cleaning validation. FDA also reviewed product labeling and found Geologie Acne Control Body Wash and Perricone MD Acne Relief Maximum Strength Spot Gel to be unapproved new drugs and misbranded.
What FDA found
The company did not thoroughly investigate out-of-specification results and batch discrepancies, identify root causes, or assess impact on other batches and marketed products.
21 CFR 211.192The company did not adequately test each incoming component lot for identity and conformity, and did not establish the reliability of suppliers' certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not adequately test high-risk incoming components for hazardous impurities and identity before using them in drug products.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not adequately validate manufacturing processes after major changes or complete validation protocols, and did not adequately validate cleaning processes or investigate out-of-specification cleaning swab results.
21 CFR 211.100(a)The acne products are unapproved new drugs and misbranded because their labeled active ingredients do not conform to the OTC acne monograph.
FD&C Act sections 505(a), 502(ee), 301(a), 301(d); 21 U.S.C. 355(a), 352(ee), 331(a), 331(d)The company’s quality oversight was inadequate and its quality unit lacked proper authority.
21 CFR parts 210 and 211
What FDA wants
FDA tells the company to promptly address the violations and provide comprehensive independent assessments and action plans for its investigation, CAPA, change management, material, validation, and cleaning systems, including risk assessments and customer notification or recall actions for affected products. The letter does not state a response deadline.
Who should pay attention
- brands that use Bentley Laboratories as a contract manufacturer
- companies selling OTC acne products
- buyers of high-risk drug ingredients such as glycerin
This is a summary. Read the original letter on fda.gov.